Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL)

被引：8

作者：

Topp, Max S. ^{[1
]}

Zugmaier, Gerhard ^{[2
]}

Goekbuget, Nicola ^{[3
]}

Kufer, Peter ^{[2
]}

Goebeler, Mariele ^{[1
]}

Klinger, Matthias ^{[2
]}

Degenhard, Evelyn ^{[2
]}

Baeuerle, Patrick A. ^{[2
]}

Schmidt, Margit ^{[2
]}

Nagorsen, Dirk ^{[2
]}

Neumann, Svenja ^{[4
]}

Horst, Heinz A. ^{[4
]}

Raff, Thorsten ^{[4
]}

Viardot, Andreas ^{[5
]}

Stelljes, Matthias ^{[6
]}

Schmid, Mathias ^{[5
]}

Ottmann, Oliver G. ^{[3
]}

Burmeister, Thomas ^{[7
]}

Einsele, Hermann ^{[1
]}

Riethmueller, Gert ^{[8
]}

Hoelzer, Dieter ^{[3
]}

Bargou, Ralf C. ^{[1
]}

机构：

[1] Univ Hosp Wurzburg, Dept Hematol & Oncol, Wurzburg, Germany

[2] Micromet AG, Munich, Germany

[3] Goethe Univ Frankfurt, Dept Med 2, Frankfurt, Germany

[4] Univ Hosp Schleswig Holstein Kiel, Poliklin, Kiel, Germany

[5] Univ Hosp Ulm, Ulm, Germany

[6] Univ Munster, Dept Hematol Oncol, Munster, Germany

[7] Charite Ctr 14, Berlin, Germany

[8] Univ Munich, Inst Immunol, D-8000 Munich, Germany

来源：

关键词：

D O I：

10.1182/blood.V114.22.840.840

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：346 / 346

页数：1